CFTR activity is enhanced by the novel corrector GLPG2222, given with and without ivacaftor in two randomized trials
GLPG1837, a CFTR potentiator, in p.Gly551Asp (G551D)-CF patients: An open-label, single-arm, phase 2a study (SAPHIRA1)
CFTR potentiator therapy ameliorates impaired insulin secretion in CF patients with a gating mutation